ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE